Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Keytruda (pembrolizumab)
pCPA File Number:
20928
Negotiation Status:
Concluded with an LOI
Indication(s):
Non-small Cell Lung Cancer
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
pCODR 10101
pCPA Engagement Letter Issued:
2017-09-08
Negotiation Process Concluded:
2017-11-01